{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:01:02Z","timestamp":1767153662082,"version":"build-2238731810"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010605","name":"Office of Vice Chancellor for Research and Technology, University of Isfahan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-10452-w","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T04:06:29Z","timestamp":1752725189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adrenocortical carcinoma survival gene HMMR was identified as being targeted by fluorouracil and epirubicin using a gene coexpression network-based drug repositioning strategy"],"prefix":"10.1038","volume":"15","author":[{"given":"Zahra","family":"Jafari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed-Morteza","family":"Javadirad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyede Elmira","family":"Yazdi Rouholamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"10452_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrendo.2010.235","volume":"7","author":"M Fassnacht","year":"2011","unstructured":"Fassnacht, M., Lib\u00e9, R., Kroiss, M. & Allolio, B. Adrenocortical carcinoma: A clinician\u2019s update. Nat. Rev. Endocrinol. 7, 323\u2013335 (2011).","journal-title":"Nat. Rev. Endocrinol."},{"key":"10452_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/amj.2020.01.07","volume":"5","author":"JE Hallanger-Johnson","year":"2020","unstructured":"Hallanger-Johnson, J. E. Systemic therapy for adrenocortical carcinoma: A review. AME Med. J. 5, 5\u20135 (2020).","journal-title":"AME Med. J."},{"key":"10452_CR3","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1210\/jc.2016-2894","volume":"102","author":"A Berruti","year":"2017","unstructured":"Berruti, A. et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 102, 1358\u20131365 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10452_CR4","doi-asserted-by":"crossref","unstructured":"Yuan, M. et al. (2022). A gene co-expression network-based drug repositioning approach identifies candidates for treatment of hepatocellular carcinoma. Cancers (Basel). 14, 1573","DOI":"10.3390\/cancers14061573"},{"key":"10452_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115539","volume":"167","author":"J Xu","year":"2023","unstructured":"Xu, J., Koval, A. & Katanaev, V. L. Clofazimine: A journey of a drug. Biomed. Pharmacother. 167, 115539 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"10452_CR6","doi-asserted-by":"publisher","first-page":"eabd5524","DOI":"10.1126\/scitranslmed.abd5524","volume":"13","author":"CG Begley","year":"2021","unstructured":"Begley, C. G. et al. Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. Sci. Transl. Med. 13, eabd5524 (2021).","journal-title":"Sci. Transl. Med."},{"key":"10452_CR7","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.7150\/ijbs.24612","volume":"14","author":"H Xue","year":"2018","unstructured":"Xue, H., Li, J., Xie, H. & Wang, Y. Review of drug repositioning approaches and resources. Int. J. Biol. Sci. 14, 1232\u20131244 (2018).","journal-title":"Int. J. Biol. Sci."},{"key":"10452_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T. & Thor, K. B. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673\u2013683 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10452_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/bib\/bbr011","volume":"12","author":"V Joachim Haupt","year":"2011","unstructured":"Joachim Haupt, V. & Schroeder, M. Old friends in new guise: Repositioning of known drugs with structural bioinformatics. Brief. Bioinform. 12, 312\u2013326 (2011).","journal-title":"Brief. Bioinform."},{"key":"10452_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3390\/pharmaceutics11120677","volume":"11","author":"A Arakelyan","year":"2019","unstructured":"Arakelyan, A. et al. Transcriptome-guided drug repositioning. Pharmaceutics 11, 677 (2019).","journal-title":"Pharmaceutics"},{"key":"10452_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-62703-748-8_4","volume":"1107","author":"T Can","year":"2014","unstructured":"Can, T. Introduction to bioinformatics. Methods Mol. Biol. 1107, 51\u201371 (2014).","journal-title":"Methods Mol. Biol."},{"key":"10452_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: An R package for weighted correlation network analysis. BMC Bioinform. 9, 559 (2008).","journal-title":"BMC Bioinform."},{"key":"10452_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-2105-8-22","volume":"8","author":"AM Yip","year":"2007","unstructured":"Yip, A. M. & Horvath, S. Gene network interconnectedness and the generalized topological overlap measure. BMC Bioinform. 8, 22 (2007).","journal-title":"BMC Bioinform."},{"key":"10452_CR14","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"8","author":"CH Chin","year":"2014","unstructured":"Chin, C. H. et al. cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 8, S11 (2014).","journal-title":"BMC Syst. Biol."},{"key":"10452_CR15","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."},{"key":"10452_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: Digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","journal-title":"Genome Biol."},{"key":"10452_CR17","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"10452_CR18","doi-asserted-by":"publisher","first-page":"D1144","DOI":"10.1093\/nar\/gkaa1084","volume":"49","author":"SL Freshour","year":"2021","unstructured":"Freshour, S. L. et al. Integration of the drug-gene interaction database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. 49, D1144\u2013D1151 (2021).","journal-title":"Nucleic Acids Res."},{"key":"10452_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41574-019-0228-0","volume":"15","author":"G Russell","year":"2019","unstructured":"Russell, G. & Lightman, S. The human stress response. Nat. Rev. Endocrinol. 15, 525\u2013534 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"10452_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41574-021-00491-4","volume":"17","author":"R Lyraki","year":"2021","unstructured":"Lyraki, R. & Schedl, A. Adrenal cortex renewal in health and disease. Nat. Rev. Endocrinol. 17, 421\u2013434 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"10452_CR21","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1038\/sj.onc.1208615","volume":"24","author":"SL Harris","year":"2005","unstructured":"Harris, S. L. & Levine, A. J. The p53 pathway: Positive and negative feedback loops. Oncogene 24, 2899\u20132908 (2005).","journal-title":"Oncogene"},{"key":"10452_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/ncb1903","volume":"11","author":"RK Singh","year":"2009","unstructured":"Singh, R. K., Kabbaj, M. H. M., Paik, J. & Gunjan, A. Histone levels are regulated by phosphorylation and ubiquitylation-dependent proteolysis. Nat. Cell Biol. 11, 925\u2013933 (2009).","journal-title":"Nat. Cell Biol."},{"key":"10452_CR23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3389\/fgene.2019.00821","volume":"10","author":"WH Xu","year":"2019","unstructured":"Xu, W. H. et al. Screening and Identification of potential prognostic biomarkers in adrenocortical carcinoma. Front. Genet. 10, 821 (2019).","journal-title":"Front. Genet."},{"key":"10452_CR24","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1111\/jcmm.15102","volume":"24","author":"J Guo","year":"2020","unstructured":"Guo, J. et al. Identification of hub genes and pathways in adrenocortical carcinoma by integrated bioinformatic analysis. J. Cell. Mol. Med. 24, 4428\u20134438 (2020).","journal-title":"J. Cell. Mol. Med."},{"key":"10452_CR25","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.7150\/jca.26698","volume":"9","author":"H Xiao","year":"2018","unstructured":"Xiao, H. et al. Identification of five genes as a potential biomarker for predicting progress and prognosis in adrenocortical carcinoma. J. Cancer 9, 4484\u20134495 (2018).","journal-title":"J. Cancer"},{"key":"10452_CR26","first-page":"4667","volume":"18","author":"Z Xing","year":"2019","unstructured":"Xing, Z., Luo, Z., Yang, H., Huang, Z. & Liang, X. Screening and identification of key biomarkers in adrenocortical carcinoma based on bioinformatics analysis. Oncol. Lett. 18, 4667\u20134676 (2019).","journal-title":"Oncol. Lett."},{"key":"10452_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.canlet.2021.05.011","volume":"514","author":"A Lin","year":"2021","unstructured":"Lin, A. et al. High levels of truncated RHAMM cooperate with dysfunctional p53 to accelerate the progression of pancreatic cancer. Cancer Lett. 514, 79\u201389 (2021).","journal-title":"Cancer Lett."},{"key":"10452_CR28","doi-asserted-by":"publisher","first-page":"e28672","DOI":"10.7554\/eLife.28672","volume":"6","author":"M Connell","year":"2017","unstructured":"Connell, M. et al. HMMR acts in the PLK1-dependent spindle positioning pathway and supports neural development. Elife 6, e28672 (2017).","journal-title":"Elife"},{"key":"10452_CR29","doi-asserted-by":"publisher","first-page":"11867","DOI":"10.1080\/21655979.2022.2060162","volume":"13","author":"Y Li","year":"2022","unstructured":"Li, Y., Yang, X. & Lu, D. Knockdown of ubiquitin-conjugating enzyme E2T (UBE2T) suppresses lung adenocarcinoma progression via targeting fibulin-5 (FBLN5). Bioengineered 13, 11867\u201311880 (2022).","journal-title":"Bioengineered"},{"key":"10452_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3727\/096504016X14685034103310","volume":"24","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Knockdown of UBE2T inhibits osteosarcoma cell proliferation, migration, and invasion by suppressing the PI3K\/Akt signaling pathway. Oncol. Res. 24, 361\u2013369 (2016).","journal-title":"Oncol. Res."},{"key":"10452_CR31","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.3748\/wjg.v25.i43.6386","volume":"25","author":"J Guo","year":"2019","unstructured":"Guo, J., Wang, M., Wang, J. P. & Wu, C. X. Ubiquitin-conjugating enzyme E2T knockdown suppresses hepatocellular tumorigenesis via inducing cell cycle arrest and apoptosis. World J. Gastroenterol. 25, 6386\u20136403 (2019).","journal-title":"World J. Gastroenterol."},{"key":"10452_CR32","doi-asserted-by":"publisher","unstructured":"Luo, C. et al. Erratum: UBE2T knockdown inhibits gastric cancer progression (Oncotarget. (2017) 8 (32639\u201332654) https:\/\/doi.org\/10.18632\/oncotarget.15947). Oncotarget 14, 188\u2013189 (2023).","DOI":"10.18632\/oncotarget.15947"},{"key":"10452_CR33","doi-asserted-by":"publisher","first-page":"8752","DOI":"10.1158\/0008-5472.CAN-09-1809","volume":"69","author":"T Ueki","year":"2009","unstructured":"Ueki, T. et al. Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. Cancer Res. 69, 8752\u20138760 (2009).","journal-title":"Cancer Res."},{"key":"10452_CR34","first-page":"937","volume":"42","author":"Y Wu","year":"2019","unstructured":"Wu, Y. et al. Identification and characterization of sexual dimorphism-linked gene expression profile in hepatocellular carcinoma. Oncol. Rep. 42, 937\u2013952 (2019).","journal-title":"Oncol. Rep."},{"key":"10452_CR35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/neup.12845","volume":"43","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Identification and characterization of sex-dependent gene expression profile in glioblastoma. Neuropathology 43, 72\u201383 (2023).","journal-title":"Neuropathology"},{"key":"10452_CR36","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2217\/pgs-2021-0031","volume":"22","author":"C Ioannou","year":"2021","unstructured":"Ioannou, C. et al. Gender-dependent association of TYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity. Pharmacogenomics 22, 669\u2013680 (2021).","journal-title":"Pharmacogenomics"},{"key":"10452_CR37","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3389\/fonc.2019.01574","volume":"9","author":"YJ Kim","year":"2020","unstructured":"Kim, Y. J. et al. UBE2C overexpression aggravates patient outcome by promoting estrogen-dependent\/independent cell proliferation in early hormone receptor-positive and HER2-negative breast cancer. Front. Oncol. 9, 1574 (2020).","journal-title":"Front. Oncol."},{"key":"10452_CR38","doi-asserted-by":"publisher","first-page":"1532658","DOI":"10.3389\/fphar.2025.1532658","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang, X., Yang, C., Liu, Y. & Wang, J. SUMOylation substrate encoding genes as prognostic biomarkers in pancreatic ductal adenocarcinoma with functional assessment of SAF-B2. Front. Pharmacol. 16, 1532658 (2025).","journal-title":"Front. Pharmacol."},{"key":"10452_CR39","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.2174\/1386207326666230110115804","volume":"26","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y., Dong, Y., Sun, Q. & Fang, C. Diagnosis and prognosis of non-small cell lung cancer based on machine learning algorithms. Comb. Chem. High Throughput Screen. 26, 2170\u20132183 (2023).","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10452_CR40","first-page":"1","volume":"2022","author":"F Xu","year":"2022","unstructured":"Xu, F., Xiong, N., Yuan, Y. & Liu, J. Prognostic value of UBE2T and its correlation with immune infiltrates in lung adenocarcinoma. J. Oncol. 2022, 1\u20139 (2022).","journal-title":"J. Oncol."},{"key":"10452_CR41","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.7150\/jca.92473","volume":"15","author":"D Cai","year":"2024","unstructured":"Cai, D., Tian, F., Wu, M., Tu, J. & Wang, Y. UBE2C is a diagnosis and therapeutic biomarker involved in immune infiltration of cancers including lung adenocarcinoma. J. Cancer 15, 1701\u20131717 (2024).","journal-title":"J. Cancer"},{"key":"10452_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.106213","volume":"151","author":"X Ma","year":"2022","unstructured":"Ma, X. et al. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma. Comput. Biol. Med. 151, 106213 (2022).","journal-title":"Comput. Biol. Med."},{"key":"10452_CR43","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.21037\/tau-24-359","volume":"13","author":"H Tang","year":"2024","unstructured":"Tang, H. et al. Identification of BIRC5 and HMMR as prognostic biomarkers for immune infiltration in prostate cancer. Transl. Androl. Urol. 13, 2482\u20132497 (2024).","journal-title":"Transl. Androl. Urol."},{"key":"10452_CR44","doi-asserted-by":"publisher","first-page":"1365206","DOI":"10.3389\/fimmu.2024.1365206","volume":"15","author":"G Li","year":"2024","unstructured":"Li, G., Yan, K., Zhang, W., Pan, H. & Guo, P. ARDS and aging: TYMS emerges as a promising biomarker and therapeutic target. Front. Immunol. 15, 1365206 (2024).","journal-title":"Front. Immunol."},{"key":"10452_CR45","doi-asserted-by":"publisher","first-page":"847","DOI":"10.21037\/tcr-23-1474","volume":"13","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y. et al. Upregulation of RACGAP1 is correlated with poor prognosis and immune infiltration in hepatocellular carcinoma. Transl. Cancer Res. 13, 847\u2013863 (2024).","journal-title":"Transl. Cancer Res."},{"key":"10452_CR46","doi-asserted-by":"crossref","unstructured":"Pu, J. et al. FOXA1\/UBE2T inhibits CD8+T cell activity by inducing mediates glycolysis in lung adenocarcinoma. Front. Biosci. - Landmark 29, 134-null (2024).","DOI":"10.31083\/j.fbl2904134"},{"key":"10452_CR47","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H., Orhan, A., Christensen, J. P. & G\u00f6genur, I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br. J. Cancer 124, 359\u2013367 (2021).","journal-title":"Br. J. Cancer"},{"key":"10452_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12032-014-0352-6","volume":"32","author":"C Yang","year":"2015","unstructured":"Yang, C. et al. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10\/STAT3\/bcl-2 signaling pathway. Med. Oncol. 32, 14 (2015).","journal-title":"Med. Oncol."},{"key":"10452_CR49","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-14-3587","volume":"75","author":"R Hughes","year":"2015","unstructured":"Hughes, R. et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res. 75, 3479\u20133491 (2015).","journal-title":"Cancer Res."},{"key":"10452_CR50","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-09-2904","volume":"16","author":"W Zhang","year":"2010","unstructured":"Zhang, W. et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 16, 3420\u20133430 (2010).","journal-title":"Clin. Cancer Res."},{"key":"10452_CR51","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.2147\/OTT.S198126","volume":"12","author":"C Wei","year":"2019","unstructured":"Wei, C. et al. M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22\/PI3K\/AKT signaling. Onco. Targets. Ther. 12, 3051\u20133063 (2019).","journal-title":"Onco. Targets. Ther."},{"key":"10452_CR52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jim.2015.03.013","volume":"420","author":"JR Potas","year":"2015","unstructured":"Potas, J. R., Haque, F., Maclean, F. L. & Nisbet, D. R. Interleukin-10 conjugated electrospun polycaprolactone (PCL) nanofibre scaffolds for promoting alternatively activated (M2) macrophages around the peripheral nerve in vivo. J. Immunol. Methods 420, 38\u201349 (2015).","journal-title":"J. Immunol. Methods"},{"key":"10452_CR53","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu, J., Geng, X., Hou, J. & Wu, G. New insights into M1\/M2 macrophages: key modulators in cancer progression. Cancer Cell Int. 21, 389 (2021).","journal-title":"Cancer Cell Int."},{"key":"10452_CR54","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799\u2013820 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10452_CR55","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/cancers13081946","volume":"13","author":"E Cendrowicz","year":"2021","unstructured":"Cendrowicz, E., Sas, Z., Bremer, E. & Rygiel, T. P. The role of macrophages in cancer development and therapy. Cancers (Basel). 13, 1946 (2021).","journal-title":"Cancers (Basel)."},{"key":"10452_CR56","first-page":"13","volume":"68","author":"U Waszut","year":"2017","unstructured":"Waszut, U., Szyszka, P. & Dworakowska, D. Understanding mitotane mode of action. J. Physiol. Pharmacol. 68, 13\u201326 (2017).","journal-title":"J. Physiol. Pharmacol."},{"key":"10452_CR57","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1200\/JCO.2008.17.2775","volume":"27","author":"I Veytsman","year":"2009","unstructured":"Veytsman, I., Nieman, L. & Fojo, T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J. Clin. Oncol. 27, 4619\u20134629 (2009).","journal-title":"J. Clin. Oncol."},{"key":"10452_CR58","first-page":"62","volume":"14","author":"RM Paragliola","year":"2018","unstructured":"Paragliola, R. M. et al. Role of mitotane in adrenocortical carcinoma - Review and state of the art. Eur. Endocrinol. 14, 62\u201366 (2018).","journal-title":"Eur. Endocrinol."},{"key":"10452_CR59","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1210\/jc.2012-2851","volume":"98","author":"V Chortis","year":"2013","unstructured":"Chortis, V. et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5\u03b1-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J. Clin. Endocrinol. Metab. 98, 161\u2013171 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10452_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EO-21-0021","volume":"2","author":"N Gagnon","year":"2022","unstructured":"Gagnon, N. et al. Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma. Endocr. Oncol. 2, 1\u20138 (2022).","journal-title":"Endocr. Oncol."},{"key":"10452_CR61","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","volume":"75","author":"M Kroiss","year":"2011","unstructured":"Kroiss, M., Quinkler, M., Lutz, W. K., Allolio, B. & Fassnacht, M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin. Endocrinol. (Oxf) 75, 585\u2013591 (2011).","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10452_CR62","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/00007611-198603000-00037","volume":"79","author":"PG Cuddy","year":"1986","unstructured":"Cuddy, P. G. & Loftus, L. S. Influence of mitotane on the hypoprothrombinemic effect of warfarin. South. Med. J. 79, 387\u2013388 (1986).","journal-title":"South. Med. J."},{"key":"10452_CR63","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1111\/bcp.14721","volume":"87","author":"CR Corso","year":"2021","unstructured":"Corso, C. R. et al. Pharmacological profile and effects of mitotane in adrenocortical carcinoma. Br. J. Clin. Pharmacol. 87, 2698\u20132710 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10452_CR64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else, T. et al. Adrenocortical carcinoma. Endocr. Rev. 35, 282\u2013326 (2014).","journal-title":"Endocr. Rev."},{"key":"10452_CR65","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1297\/cpe.17.71","volume":"17","author":"T Goto","year":"2008","unstructured":"Goto, T. et al. Case report: Adjuvant therapy with a high dose of mitotane for adrenocortical carcinoma in a 4-year-old boy. Clin. Pediatr. Endocrinol. 17, 71\u201374 (2008).","journal-title":"Clin. Pediatr. Endocrinol."},{"key":"10452_CR66","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari, S. & Bernard Tchounwou, P. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 740, 364\u2013378 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"10452_CR67","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.etp.2009.02.066","volume":"62","author":"A Kart","year":"2010","unstructured":"Kart, A., Cigremis, Y., Karaman, M. & Ozen, H. Caffeic acid phenethyl ester (CAPE) ameliorates cisplatin-induced hepatotoxicity in rabbit. Exp. Toxicol. Pathol. 62, 45\u201352 (2010).","journal-title":"Exp. Toxicol. Pathol."},{"key":"10452_CR68","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1742-7843.2006.00024.x","volume":"100","author":"AA Al-Majed","year":"2007","unstructured":"Al-Majed, A. A. Carnitine deficiency provokes cisplatin-induced hepatotoxicity in rats. Basic Clin. Pharmacol. Toxicol. 100, 145\u2013150 (2007).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10452_CR69","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/sj.bjc.6600884","volume":"88","author":"FE De Jongh","year":"2003","unstructured":"De Jongh, F. E. et al. Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients. Br. J. Cancer 88, 1199\u20131206 (2003).","journal-title":"Br. J. Cancer"},{"key":"10452_CR70","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/0277-5379(91)90549-S","volume":"27","author":"FPT Hamers","year":"1991","unstructured":"Hamers, F. P. T., Gispen, W. H. & Neijt, J. P. Neurotoxic side-effects of cisplatin. Eur. J. Cancer Clin. Oncol. 27, 372\u2013376 (1991).","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10452_CR71","first-page":"e13807","volume":"97","author":"Y Hu","year":"2018","unstructured":"Hu, Y. et al. Cisplatin-induced cardiotoxicity with midrange ejection fraction: A case report and review of the literature. Med. (United States) 97, e13807 (2018).","journal-title":"Med. (United States)"},{"key":"10452_CR72","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.fct.2009.02.007","volume":"47","author":"MI Yousef","year":"2009","unstructured":"Yousef, M. I., Saad, A. A. & El-Shennawy, L. K. Protective effect of grape seed proanthocyanidin extract against oxidative stress induced by cisplatin in rats. Food Chem. Toxicol. 47, 1176\u20131183 (2009).","journal-title":"Food Chem. Toxicol."},{"key":"10452_CR73","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1080\/13813455.2020.1773864","volume":"128","author":"M Najafi","year":"2022","unstructured":"Najafi, M., Tavakol, S., Zarrabi, A. & Ashrafizadeh, M. Dual role of quercetin in enhancing the efficacy of cisplatin in chemotherapy and protection against its side effects: A review. Arch. Physiol. Biochem. 128, 1438\u20131452 (2022).","journal-title":"Arch. Physiol. Biochem."},{"key":"10452_CR74","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1590\/S0100-879X2000001000009","volume":"33","author":"DE Schteingart","year":"2000","unstructured":"Schteingart, D. E. Conventional and novel strategies in the treatment of adrenocortical cancer. Brazilian J. Med. Biol. Res. 33, 1197\u20131200 (2000).","journal-title":"Brazilian J. Med. Biol. Res."},{"key":"10452_CR75","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht, M. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189\u20132197 (2012).","journal-title":"N. Engl. J. Med."},{"key":"10452_CR76","first-page":"50","volume":"6","author":"D Kandioler-Eckersberger","year":"2000","unstructured":"Kandioler-Eckersberger, D. et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res. 6, 50\u201356 (2000).","journal-title":"Clin. Cancer Res."},{"key":"10452_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189024","volume":"1878","author":"A Gieleci\u0144ska","year":"2023","unstructured":"Gieleci\u0144ska, A. et al. Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents?. Biochim. Biophys. Acta - Rev. Cancer 1878, 189024 (2023).","journal-title":"Biochim. Biophys. Acta - Rev. Cancer"},{"key":"10452_CR78","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/1097-0142(19880101)61:1<36::AID-CNCR2820610108>3.0.CO;2-6","volume":"61","author":"NJ Freeman","year":"1988","unstructured":"Freeman, N. J. & Costanza, M. E. 5-Fluorouracil-associated cardiotoxicity. Cancer 61, 36\u201345 (1988).","journal-title":"Cancer"},{"key":"10452_CR79","doi-asserted-by":"publisher","unstructured":"Wigmore, P. M. et al. Effects of 5-FU. in 157\u2013164 (2010). https:\/\/doi.org\/10.1007\/978-1-4419-6306-2_20.","DOI":"10.1007\/978-1-4419-6306-2_20"},{"key":"10452_CR80","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules13081551","volume":"13","author":"N Zhang","year":"2008","unstructured":"Zhang, N., Yin, Y., Xu, S. J. & Chen, W. S. 5-Fluorouracil: Mechanisms of resistance and reversal strategies. Molecules 13, 1551\u20131569 (2008).","journal-title":"Molecules"},{"key":"10452_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102144","volume":"47","author":"C Yang","year":"2021","unstructured":"Yang, C. et al. Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells. Redox Biol. 47, 102144 (2021).","journal-title":"Redox Biol."},{"key":"10452_CR82","doi-asserted-by":"publisher","first-page":"8052","DOI":"10.1074\/jbc.M610621200","volume":"282","author":"X-X Sun","year":"2007","unstructured":"Sun, X.-X., Dai, M.-S. & Lu, H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J. Biol. Chem. 282, 8052\u20138059 (2007).","journal-title":"J. Biol. Chem."},{"key":"10452_CR83","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.7150\/thno.107793","volume":"15","author":"Z Xiu","year":"2025","unstructured":"Xiu, Z. et al. A multifunctional injectable microsphere with enhanced near-infrared photo-antibacterial, ROS scavenging, and anti-inflammatory properties for periodontitis treatment. Theranostics 15, 3750\u20133780 (2025).","journal-title":"Theranostics"},{"key":"10452_CR84","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1172\/JCI6863","volume":"104","author":"F Bunz","year":"1999","unstructured":"Bunz, F. et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263\u2013269 (1999).","journal-title":"J. Clin. Invest."},{"key":"10452_CR85","doi-asserted-by":"publisher","first-page":"788331","DOI":"10.3389\/fcell.2021.788331","volume":"9","author":"X Gao","year":"2022","unstructured":"Gao, X. et al. Deficient or R273H and R248W mutations of p53 promote chemoresistance to 5-FU via TCF21\/CD44 axis-mediated enhanced stemness in colorectal carcinoma. Front. Cell Dev. Biol. 9, 788331 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"10452_CR86","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.2147\/OTT.S302334","volume":"14","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. et al. Gdc-0326 enhances the effects of 5-fu in colorectal cancer cells by inducing necroptotic death. Onco. Targets. Ther. 14, 2519\u20132530 (2021).","journal-title":"Onco. Targets. Ther."},{"key":"10452_CR87","doi-asserted-by":"publisher","first-page":"zcac035","DOI":"10.1093\/narcan\/zcac035","volume":"4","author":"R Dutta","year":"2022","unstructured":"Dutta, R. et al. UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress. NAR Cancer 4, zcac035 (2022).","journal-title":"NAR Cancer"},{"key":"10452_CR88","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13048-022-01034-9","volume":"15","author":"P Cui","year":"2022","unstructured":"Cui, P. et al. UBE2T regulates epithelial\u2013mesenchymal transition through the PI3K-AKT pathway and plays a carcinogenic role in ovarian cancer. J. Ovarian Res. 15, 103 (2022).","journal-title":"J. Ovarian Res."},{"key":"10452_CR89","first-page":"1212","volume":"20","author":"P Hao","year":"2019","unstructured":"Hao, P., Kang, B., Li, Y., Hao, W. & Ma, F. UBE2T promotes proliferation and regulates PI3K\/Akt signaling in renal cell carcinoma. Mol. Med. Rep. 20, 1212\u20131220 (2019).","journal-title":"Mol. Med. Rep."},{"key":"10452_CR90","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/1535-7163.MCT-11-0024","volume":"10","author":"J Millour","year":"2011","unstructured":"Millour, J. et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol. Cancer Ther. 10, 1046\u20131058 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"10452_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012341","volume":"5","author":"D Nantajit","year":"2010","unstructured":"Nantajit, D. et al. Cyclin B1\/Cdk1 phosphorylation of mitochondrial p53 induces anti-apoptotic response. PLoS One 5, e12341 (2010).","journal-title":"PLoS One"},{"key":"10452_CR92","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12967-022-03277-y","volume":"20","author":"Y Huang","year":"2022","unstructured":"Huang, Y., Li, D., Wang, L., Su, X. & Tang, X. CENPF\/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2\/M-phase cell cycle. J. Transl. Med. 20, 78 (2022).","journal-title":"J. Transl. Med."},{"key":"10452_CR93","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/j.1349-7006.2009.01150.x","volume":"100","author":"K Kojima","year":"2009","unstructured":"Kojima, K., Shimanuki, M., Shikami, M., Andreeff, M. & Nakakuma, H. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated bax activation and mitochondrial apoptosis in AML. Cancer Sci. 100, 1128\u20131136 (2009).","journal-title":"Cancer Sci."},{"key":"10452_CR94","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.1002\/cam4.3513","volume":"9","author":"JL Lu","year":"2020","unstructured":"Lu, J. L. et al. Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: A systematic review and network meta-analysis. Cancer Med. 9, 7800\u20137809 (2020).","journal-title":"Cancer Med."},{"key":"10452_CR95","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2147\/IJN.S189688","volume":"14","author":"N Suo","year":"2019","unstructured":"Suo, N. et al. Magnetic multiwalled carbon nanotubes with controlled release of epirubicin: An intravesical instillation system for bladder cancer. Int. J. Nanomedicine 14, 1241\u20131254 (2019).","journal-title":"Int. J. Nanomedicine"},{"key":"10452_CR96","doi-asserted-by":"publisher","first-page":"98737","DOI":"10.5498\/wjp.v15.i1.98737","volume":"15","author":"J Liu","year":"2025","unstructured":"Liu, J., Guo, Y.-P., Lu, Y.-M. & Wang, B.-L. Clinical value of combining epirubicin with mindfulness intervention in patients with urinary system tumors and depression. World J. psychiatry 15, 98737 (2025).","journal-title":"World J. psychiatry"}],"updated-by":[{"DOI":"10.1038\/s41598-025-26111-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10452-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10452-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10452-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T08:03:25Z","timestamp":1762934605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10452-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10452"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-10452-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-26111-z","URL":"https:\/\/doi.org\/10.1038\/s41598-025-26111-z","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Each author confirms that their research is supported by an institution that is primarily involved in education or research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"25912"}}